CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
BI 1015550drug
Likely dose
BI 1015550 18 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06415045
NCT06415045Phase 1Completed
CompareCT.gov

The Effect of Food on the Pharmacokinetics of BI 1015550 (Formulation C2) Following Single Oral Dose Administration in Healthy Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Design)

Boehringer Ingelheim·interventional·Posted May 16, 2024·Updated Dec 1, 2025

In Brief

A Phase 1 clinical trial evaluating BI 1015550 for Healthy. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The main objective is to investigate the effect of food on the pharmacokinetics of BI 1015550 Formulation C2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedMay 16, 2024
Enrollment StartMay 28, 2024
Primary CompletionJul 24, 2024
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.1 years ago

Interventions

BI 1015550drug

Participants received a single 18 mg Nerandomilast Formulation C2 film-coated tablet either after an overnight fast of at least 10 hours or following a high-fat, high-calorie meal.